Stand-on Ride-on Power Mobility Devices for Children With Cerebral Palsy
August 24, 2026 updated by: Guilherme M Cesar, University of North Florida
Biomechanical Changes Underpinning Stand-on Ride-on Power Mobility Devices for Children With Cerebral Palsy
The goal of this interventional study is to learn about the biomechanical factors underlying the beneficial changes in children with cerebral palsy after using individually-adapted stand-on ride-on power mobility devices (PMD).
The main questions we aim to answer are:
- How does the use of stand-on PMDs affect static balance in children with cerebral palsy?
- How does the use of stand-on PMDs affect dynamic balance and mobility function in children with cerebral palsy?
Children ages 4-6 years old with cerebral palsy (GMFCS levels II and III) will:
- Use individually-adapted stand-on PMDs for three months.
- Undergo tests to measure static balance, dynamic balance, and mobility function before and after the intervention.
- Receive a full biomechanical assessment (kinematics, kinetics, muscle activity, gait spatiotemporal characteristics).
Researchers will compare pre-intervention and post-intervention measurements to quantify improvements in balance, muscle activation, and mobility.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- University of North Florida
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of spastic diplegia CP, GMFCS level III;
- Between 4 and 6 years old (age band selected based on the benefits of early intervention and the age-limitation imposed from the size constraints of the PMDs (toy cars) selected for the intervention);
- Able to stand and to walk short distances (at least 10 meters) with or without external assistance;
- Physician medical clearance to participate; and
- Exhibit sufficient cooperation and attention so that simple verbal instructions can be followed.
Exclusion Criteria:
- Have notable orthopedic conditions (e.g., lower extremity amputation; recent hip surgeries or soft tissue lengthening);
- Inadequate vision to complete study's procedures safely;
- Serious/unstable cardiac conditions that prevent engagement in the Evaluation Sessions; and
- Any other factor that might hinder full participation in the study or confound interpretation of the results.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention Group
Children with cerebral palsy received an individually adapted stand-on ride-on powered mobility device for home and community use over a three-month intervention period.
Participants completed biomechanical assessments before and after the intervention.
|
Children will receive the adapted toy car (individually-adapted stand-on PMD) to take home and use for three months.
PMD will be used at their house and familiar environments to the family (e.g., neighborhood, parks, schools).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Center of Pressure Sway Area, Standing
Time Frame: Pre (immediately before intervention), Post (3 months post Pre)
|
Center of pressure sway area during quiet standing was quantified as the 95% confidence ellipse area derived from force plate measurements.
Larger sway area values indicate greater postural sway and reduced standing balance stability.
Reported values represent the absolute measurements obtained during each of the pre-intervention and post-intervention assessments.
For participants completing multiple standing trials at an assessment, the participant-level median across trials was used for analysis.
The reported values represent the group median of the participant-level medians for the pre-intervention and post-intervention assessments.
|
Pre (immediately before intervention), Post (3 months post Pre)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Center of Pressure Sway Area, Sit-to-stand
Time Frame: Pre (immediately before intervention), Post (3 months post Pre)
|
Measure of dynamic balance control during sit-to-stand.
Center of pressure sway area during quiet standing was quantified as the 95% confidence ellipse area derived from force plate measurements.
Larger ellipse areas indicate greater postural sway.
Reported values represent the absolute measurements obtained during each of the pre-intervention and post-intervention assessments.
For participants completing multiple standing trials at an assessment, the participant-level median across trials was used for analysis.
The reported values represent the group median of the participant-level medians for the pre-intervention and post-intervention assessments.
|
Pre (immediately before intervention), Post (3 months post Pre)
|
|
Trunk-pelvis Coupling
Time Frame: Baseline, Pre (3 months post Baseline), Post (3 months post Pre)
|
Quantification of timing and magnitude of whole-body motor control coordination during functional tasks (e.g., sit-to-stand, walking turns).
Trunk-pelvis coupling was quantified using vector coding analysis to characterize coordination between trunk and pelvis motion during the movement task.
Reported values represent the absolute measurements obtained during each of the pre-intervention and post-intervention assessments.
For participants completing multiple trials at an assessment, the participant-level median across trials was used for analysis.
The reported values represent the group median of the participant-level medians for the pre-intervention and post-intervention assessments.
|
Baseline, Pre (3 months post Baseline), Post (3 months post Pre)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2024
Primary Completion (Actual)
December 31, 2025
Study Completion (Actual)
July 31, 2026
Study Registration Dates
First Submitted
June 6, 2024
First Submitted That Met QC Criteria
June 6, 2024
First Posted (Actual)
June 12, 2024
Study Record Updates
Last Update Posted (Actual)
August 28, 2026
Last Update Submitted That Met QC Criteria
August 24, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UNFlorida
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
Further discussion is needed given vulnerable population.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.